Cisplatin, radiation, and amifostine in carcinoma of the uterine cervix

International Journal of Gynecological Cancer

Volumn 9, Issue 3, 1999, Pages 225-230

  Gallardo, D ^a   Mohar, A ^a   Calderillo, G ^a   Mota, A ^a   Solorza, G ^a   Lozano, A ^a   Solano, P ^a   De La Garza, J ^a  

^a INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

Author keywords

Amifostine; Cervical cancer; Cisplatin; Mexico; Radiotherapy

Indexed keywords

AMIFOSTINE; CISPLATIN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HISTOPATHOLOGY; HUMAN; HYPOCALCEMIA; HYPOTENSION; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; UTERINE CERVIX CARCINOMA;

EID: 0032968674     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.1999.99029.x     Document Type: Article

References (29)

1. Herrera R. Epidemiology of cervical cancer. J Natl Cancer Inst Monogr 1996; 21: 1-6.
2. Tapia R, Kuri P, Macias C, De la Garza J, Mohar A, Meneses A, eds. Compendio del Registro Histopatológico de las Neoplasias Malignas en México, Morbilidad y Mortalidad. México DF. Secretar'a de Salud, 1997.
3. Fuller AF, Elliot N, Kosloff C, Hoskins WJ, Lewis JL. Determinants of increased risk for recurrence in patients undergoing radical hysterectomy for stages Ib and IIa carcinoma of the cervix. Gynecol Oncol 1989; 33: 34-9.
4. Stehman FB, Bundy BN, Disaia PJ, Keys HM, Larson JE, Fowler WC. Carcinoma of the cervix treated with radiation therapy. A multivariate analysis of prognostic variables in the Gynecologic Oncology Group. Cancer 1991; 67: 2776-85.
5. Chang H, Lai C, Chou P et al. Neoadjuvant chemotheraoy with cisplatin, vincristine and bleomycin and radical surgery in early stage bulky cervical carcinoma. Cancer Chemother Pharmacol 1992; 30: 281-8.
6. Kim D, Moon H, Hwang Y, Cho SH. Preoperative adjuvant chemotherapy in the treatment of cervical cancer stage IB, IIA and IIIB with bulky tumor. Gynecol Oncol 1988; 29: 321-32.
7. Symonds RP, Habeshaw T, Watson ER, Kaye SB. Combination chemotherapy prior to radical radiotherapy for stage III and IV carcinoma of the cervix. Clin Radiol 1987; 38: 273-4.
8. Kirsten F, Ajkinson K, Coppleson J et al. Combination chemotherapy followed by surgery or radiotherapy in patients with locally advanced cervical cancer. Br J Obstet Gynecol 1987; 94: 583-8.
9. Yuhas JM. Active vs passive absorption kinetics as the basis for selective protection of normal tissues by S-2 (3 aminopropylamino) -ethylphosphorothioic acid. Cancer Res 1980; 40: 1519-24.
10. Treskes M, Nijtmans LGJ, Fictinger-Schepman AMJ et al. The modulating agent WR-2721 and its main metabolites on the formation and stability of cisplatin-DNA adducts in vitro in comparison to the effects of thiosulphate and diethyldithiocarbonate. Biochem Pharmacol 1992; 43: 1013-9.
11. Kemp G, Rose P, Lurain J, et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 1996; 14: 2101-12.
12. Tannehill SP, Mehta MP, Larson M et al. Phase II clinical trial of Amifostine (WR2721), cisplatin, vinblastine and thoracic irradiation therapy for unresectable stage III non small cell lung cancer [abstract], Int J Radiat Oncol Biol Phys 1995; 32 (Suppl. 1): 196.
13. Betticher DC, Anderson H, Ranson M et al. Carboplatin combined with amifostine, a bone marrow protectant in the treatment of non-small cell lung cancer. Br J Cancer 1995; 72: 1551-5.
14. Schiller JH. High dose of cisplatin and vinblastine plus amifostine for metastatic non-small cell lung cancer. Semin Oncol 1996; 23 (Suppl. 8): 78-82.
15. Wadler S, Beitler JJ, Rubin JS et al. Pilot trial of cisplatin, radiation, and WR2721 in carcinoma of the uterine cervix: A New York Gynecologic Oncology Group Study. J Clin Oncol 1993; 11: 1511-6.
16. FIGO. Classification and staging of malignant tumors in the female pelvis. Acta Obstet Gynecol Scand 1971; 50: 1-7.
17. rd edn. Boston: Little Brown; 1995 p. 503-6.
18. Ajani JA, Welch SR, Raber MN, Fields WS, Krakoff IH. Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest 1990; 8: 147-59.
19. Fachini T, Belpomme D, Kemp G et al. Amifostine selectively protects against cumulative toxicities of cyclophosphamide and cisplatin [Abstract]. Eur J Cancer 1995; 31 (Suppl. 5): 107.
20. Capizzi RL, Scheffler BJ, Schein PS. Amifostine mediated protection of normal bone marrow from cytotoxic chemotherapy. Cancer 1993; 72: 3495-501.
21. Yuhas JM, Spellman JM, Culo F. The role of amifostine in radiotherapy and or chemotherapy. Cancer Clin Trial 1980; 3: 211-7.
22. Wasserman TH, Phillips JL, Ross G et al. Differential protection against cytotoxic chemotherapeutic effects on bone marrow CFUs by WR-2721. Cancer Clin Trial 1981; 14: 3-6.
23. Yuhas JM, Spellman JM, Jordan SW. Treatment of tumours with the combination of WR-2721 and cisdichlorodiamineplatinum or cyclophosphamide. Br J Cancer 1980; 42: 574-85.
24. Sardi JE, Giaroli A, Sananes C et al. Long term follow-up of the first randomized trial using neoadjuvant chemotherapy in stage Ib squamous carcinoma of the cervix: The final results. Gynecol Oncol 1997; 67: 61-9.
25. Dottino PR, Plaxe S, Beddoe A, Johnstone Cohen CJ. Induction chemotherapy followed by radical surgery in cervical cancer Gynecol Oncol 1991; 40: 7-11.
26. Tattersall MH, Larvidhaya V, Vootiprux V et al. The randomized trial of epirubicin and cisplatin chemotherapy followed by pelvic radiation in locally advanced cervical cancer. Am J Clin Oncol 1995; 13: 444-8.
27. Omura GA. Chemotherapy for cervix cancer. Semin Oncol 1994; 2: 54-62.
28. Cannistra SP, Nicoff TM. Cancer of the uterine cervix. New Engl J Med 1996; 334: 1030-8.
29. Pignata S, DeVivo R, Richi P, Perroni F, Botti G, Monfardini S. Chemotherapy in squamous cell carcinoma of the cervix uteri: present role and perspectives. Cancer Treat Rev 1998; 24: 27-34.